Peter C. Farrell, a director at ResMed Inc. ($RMD), sold 8,000 shares of the company on August 5, 2026. Each share went for $225.00, bringing in $1,800,000 total. The open-market transaction was disclosed in a Form 4 filing on August 6, and after it, Farrell reported direct ownership of 52,773 shares.
The sale was unusual in size. From January through April 2026, Farrell had sold 2,000 shares per month, at prices ranging from $225.00 to $260.22, for combined proceeds of about $1,970,720. He then made no open-market sales in May, June, or July. The August 5 trade broke the four-month silence and was four times larger than his typical monthly move. Between January and August, his $RMD position fell from 66,773 shares to 52,773, a decline of roughly 21%. Open-market sales since June 2025 were consistently near 2,000 shares; the exception was a single 945-share sale in July 2025. The August transaction is the largest in Farrell’s available filing history.
Other insiders were active sellers in 2026. CEO Michael J. Farrell, who shares the director’s surname, sold 4,991 shares in each of six open-market trades between January and July. Those sales, on January 7, February 9, March 9, April 7, May 7, and July 7, generated approximately $7.1 million at per-share prices from $207.82 to $273.78.
CFO Brett Sandercock executed four open-market sales of 1,000 shares each: January 2, February 2, March 2, and April 1. The total proceeds were roughly $977,390. Global General Counsel Michael J. Rider sold 50 shares on January 2 and another 50 on February 4, totaling about $25,088.
Taken together, the 17 open-market sales by four insiders through August 5, 2026, produced aggregate proceeds of approximately $11.9 million.
Congressional activity in ResMed was far smaller. Representative Ro Khanna, a California Democrat, disclosed multiple purchases and sales of $RMD stock in 2026. All fell within the $1,001 to $15,000 range, the narrowest bracket on congressional forms, implying a midpoint estimate of roughly $1,001 per trade. His most recent filing, submitted in June 2026, included both a purchase and a sale. The dollar amounts involved were dwarfed by any single insider sale during the period.
ResMed, based in San Diego, manufactures sleep apnea devices and masks for respiratory care.